E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954

Prodrug activation gene therapy is a developing approach to cancer treatment, whereby prodrug-activating enzymes are expressed in tumour cells. After administration of a non-toxic prodrug, its conversion to cytotoxic metabolites directly kills tumour cells expressing the activating enzyme, whereas t...

Descripción completa

Detalles Bibliográficos
Autores principales: Vass, S O, Jarrom, D, Wilson, W R, Hyde, E I, Searle, P F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690450/
https://www.ncbi.nlm.nih.gov/pubmed/19455141
http://dx.doi.org/10.1038/sj.bjc.6605094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690450/
https://www.ncbi.nlm.nih.gov/pubmed/19455141
http://dx.doi.org/10.1038/sj.bjc.6605094

Ejemplares similares